USA - NASDAQ:ACON - US6551874091 - Common Stock
The current stock price of ACON is 7.71 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -99.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 39.11 | 47.76B | ||
| DOCS | DOXIMITY INC-CLASS A | 44.62 | 12.45B | ||
| WAY | WAYSTAR HOLDING CORP | 35.58 | 7.54B | ||
| HTFL | HEARTFLOW INC | N/A | 3.19B | ||
| CERT | CERTARA INC | 24.76 | 1.95B | ||
| SDGR | SCHRODINGER INC | N/A | 1.60B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.48B | ||
| PHR | PHREESIA INC | N/A | 1.40B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 10.46 | 1.27B | ||
| CTEV | CLARITEV CORP | N/A | 1.17B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.07B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 899.72M |
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
ACLARION INC
8181 Arista Place, Ste 100
Broomfield COLORADO US
Employees: 6
Phone: 18332752266
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
The current stock price of ACON is 7.71 USD. The price increased by 0.78% in the last trading session.
ACON does not pay a dividend.
ACON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ACON.
You can find the ownership structure of ACLARION INC (ACON) on the Ownership tab.
The outstanding short interest for ACLARION INC (ACON) is 12.32% of its float.
ChartMill assigns a technical rating of 3 / 10 to ACON. When comparing the yearly performance of all stocks, ACON is a bad performer in the overall market: 96.49% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ACON. No worries on liquidiy or solvency for ACON as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ACON reported a non-GAAP Earnings per Share(EPS) of -2155.52. The EPS increased by 93.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.85% | ||
| ROE | -49.76% | ||
| Debt/Equity | 0 |
7 analysts have analysed ACON and the average price target is 20.4 USD. This implies a price increase of 164.59% is expected in the next year compared to the current price of 7.71.
For the next year, analysts expect an EPS growth of 99.81% and a revenue growth 100% for ACON